Insights
Search Results
Client Highlights
8.05.26
Firm Advises DISA Technologies on Launch of DISA Uranium Corporation
On August 4, 2026, DISA® Technologies, a uranium recovery and production company, announced the formation of DISA Uranium™ Corporation, a new American company built to recover and produce domestic uranium and remediate the nation's legacy uranium sites. In connection with its launch, DISA Uranium has entered into a definitive agreement to acquire IsoEnergy's Utah uranium portfolio of permitted, past-producing mines and projects—giving DISA Uranium a scaled conventional resource base to pair with its proprietary processing technology and the only U.S. Nuclear Regulatory Commission license of its kind. Wilson Sonsini Goodrich & Rosati advised DISA on the transaction.
Client Highlights
6.11.26
Wilson Sonsini Advises Beren Therapeutics P.B.C. on $300 Million Financing, Including Equity and Debt and Royalty Facilities
On June 10, 2026, Beren Therapeutics P.B.C., a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, announced it has secured $300 million in combined financing. The financing consists of:
Client Highlights
4.09.26
Wilson Sonsini Advises Forte Biosciences on $150 Million Public Offering
On April 8, 2026, Forte Biosciences, Inc., a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. The gross proceeds from the offering are expected to be approximately $150 million before deducting underwriting discounts and commissions and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.
Client Highlights
3.13.26
Wilson Sonsini Advises Enodia Therapeutics on Purchase Agreement with Kezar Life Sciences
On March 12, 2026, Enodia Therapeutics (Enodia), a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, announced that Enodia has acquired Kezar’s assets from its Sec61-based discovery and development program. Under the terms of the purchase agreement between Enodia and Kezar, Kezar will receive an initial upfront payment totaling $1 million, and will receive future payments upon achievement of certain development, regulatory and commercialization milestones, for a potential total of up to $127 million. Enodia has also agreed to pay tiered royalties on net sales. Wilson Sonsini Goodrich & Rosati advised Enodia on the transaction.
Client Highlights
3.09.26
Wilson Sonsini Advises Lead Investor on SHINE’s $240 Million Equity Funding
On February 27, 2026, SHINE Technologies, a nuclear fusion company, announced it has raised $240 million in equity funding led by NantWorks founder Dr. Patrick Soon-Shiong, with additional participation from Fidelity Management & Research Company, Sumitomo Corporation of Americas, Pelican Energy Partners, Deerfield Management, Oaktree Capital Management, and other existing investors. Wilson Sonsini Goodrich & Rosati advised lead investor OZ Shine LLC—a new investment company led by Dr. Soon-Shiong—on the transaction.
Client Highlights
2.23.26
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Client Highlights
2.12.26
Wilson Sonsini Advises Delta40 on $20 Million Funding
On February 11, 2026, Delta40, an integrated venture studio and VC fund investing in and supporting founders on the frontlines of Africa’s most urgent challenges, announced $20 million in funding. The milestone marks Africa’s first institutional raise linking venture building and early-stage capital, merging investment with hands-on studio support from experienced operators to build and scale start-ups across the continent. Wilson Sonsini Goodrich & Rosati advised Delta40 on the transaction.
Delta40 initially launched its venture studio model in Kenya and has since expanded to Lagos, Nigeria, providing portfolio companies with direct, on-the-ground support as they scale across the continent. Delta40 pioneered a unique venture studio and fund model that combines early-stage capital with embedded product, fundraising, commercial, finance, legal, growth, and exit expertise. Through this model, Delta40 partners with founders from idea to scale across energy and mobility, agriculture, and fintech—with a goal to integrate AI across all sectors.
Delta40 initially launched its venture studio model in Kenya and has since expanded to Lagos, Nigeria, providing portfolio companies with direct, on-the-ground support as they scale across the continent. Delta40 pioneered a unique venture studio and fund model that combines early-stage capital with embedded product, fundraising, commercial, finance, legal, growth, and exit expertise. Through this model, Delta40 partners with founders from idea to scale across energy and mobility, agriculture, and fintech—with a goal to integrate AI across all sectors.
Client Highlights
11.05.25
Firm Advises Frontline Wildfire Defense on $48 Million Series A Funding Round
On October 28, 2025, Frontline Wildfire Defense, the leading wildfire defense solution for homes, businesses, and communities, announced it has closed a $48 million Series A round led by Norwest to scale its proven wildfire defense systems across fire-prone states. Wilson Sonsini Goodrich & Rosati advised Frontline Wildfire Defense on the transaction.
Client Highlights
10.08.25
Firm Advises Clearway on Acquisitions of Catalina Solar Facility and Deriva Energy’s Solar Portfolio
On October 6, 2025, Clearway Energy, Inc., one of the largest owners of clean energy generation assets in the U.S., announced that it has entered into a binding agreement to acquire a 613MWac portfolio of operating solar assets from Deriva Energy spanning eight states. Clearway also recently announced its acquisition of the 109 MW Catalina Solar facility in Kern County, California. Wilson Sonsini Goodrich & Rosati advised Clearway on the transactions.
Client Highlights
9.25.25
Wilson Sonsini Advises LALO Tequila on Acquisition by Tito’s
On September 23, 2025, Tito's Handmade Vodka, the brand behind Texas' first legal distillery and the award-winning vodka, announced it has entered into a definitive agreement to acquire the majority stake in LALO Tequila, one of the fastest-growing tequila brands in the United States. Wilson Sonsini Goodrich & Rosati advised LALO on the transaction.
Client Highlights
6.18.25
Firm Advises Enliven Therapeutics on $230 Million Public Offering
On June 16, 2025, Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, announced the close of its underwritten public offering of 9,920,987 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,526,250 additional shares of its common stock, at a price to the public of $19.66 per share and pre-funded warrants to purchase 1,780,263 shares of its common stock at a price to the public of $19.659 per pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven. The gross proceeds from the offering were approximately $230 million before deducting underwriting discounts and commissions and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Enliven on the offering.